Antibiotice (BSE:ATB) Other Stockholders Equity: lei640.7 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSE:ATB Antibiotice SA BSE:ATB
75 GF Score
Price lei2.19
GF Value lei2.20
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Antibiotice Other Stockholders Equity?

Antibiotice BSE:ATB +0.92% 75 Other Stockholders Equity is lei640.7 Mil as of Mar. 2026. GuruFocus rates BSE:ATB with a GF Score™ of 75/100 and a GF Value™ of lei2.20 (Fairly Valued). The stock has 6 warning signs investors should review.

Antibiotice's Other Stockholders Equity for the quarter that ended in Mar. 2026 was lei640.7 Mil.

Antibiotice's quarterly Other Stockholders Equity increased from Sep. 2025 (lei627.1 Mil) to Dec. 2025 (lei643.7 Mil) but then declined from Dec. 2025 (lei643.7 Mil) to Mar. 2026 (lei640.7 Mil).

Antibiotice's annual Other Stockholders Equity increased from Dec. 2023 (lei550.3 Mil) to Dec. 2024 (lei626.1 Mil) and increased from Dec. 2024 (lei626.1 Mil) to Dec. 2025 (lei643.7 Mil).

Antibiotice Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Antibiotice's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antibiotice Other Stockholders Equity Chart

Antibiotice Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 386.73 503.35 550.30 626.10 643.71

Antibiotice Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 623.31 629.87 627.07 643.71 640.73
BSE:ATB
75GF Score
Antibiotice SA BSE:ATB
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antibiotice Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of lei640.7 Mil mean?
Antibiotice (BSE:ATB) has a Other Stockholders Equity of lei640.7 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Antibiotice and its competitors.
Is Antibiotice's Other Stockholders Equity too high?
Antibiotice's current Other Stockholders Equity is lei640.7 Mil. Overall, Antibiotice has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Antibiotice's Other Stockholders Equity compare to ZTS and UTHR?
Antibiotice's Other Stockholders Equity of lei640.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Antibiotice and its competitors. Antibiotice's current Other Stockholders Equity is lei640.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antibiotice stock overvalued right now?
Based on GuruFocus' analysis, Antibiotice (BSE:ATB) is currently considered Fairly Valued. The stock's GF Value™ is lei2.20, compared to a current price of lei2.19 — trading 0.7% below its estimated fair value. The current Other Stockholders Equity is lei640.7 Mil. Antibiotice's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Antibiotice (BSE:ATB), the current Other Stockholders Equity is lei640.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Antibiotice (BSE:ATB) Overvalued in 2026?

Based on GuruFocus' analysis, Antibiotice stock appears to be undervalued. The current stock price of lei2.19 is trading 0.7% below its estimated GF Value™ of lei2.20. GuruFocus considers Antibiotice to be Fairly Valued.

Key valuation signals for BSE:ATB:

  • Other Stockholders Equity: lei640.7 Mil
  • GF Value™: lei2.20 vs. price of lei2.19 (0.7% below fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the BSE:ATB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Antibiotice Business Description

Address 1 Valea Lupului Street, Iasi, ROU, 707410
Antibiotice SA is a Romania based company engaged in manufacturing generic medicines. It primarily develops and produces generic medicines for human use, veterinary medicines and active substance Nystatin. The group's generic medicines are primarily targeted at patients with infections, dermatological, cardiovascular, digestive tract diseases or diseases of the musculoskeletal system. It manufactures firm powders for solutions for injection and suspensions for injection (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels, creams).
75GF Score

Get the complete analysis for BSE:ATB

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei2.19
Price
lei2.20
GF Value